This Component's long term objectives are twofold; 1) to understand normal and abnormal cardiac function in terms of the various contractile protein isoforms that are expressed; and 2) to explore the early developmental events that underlie normal and abnormal cardiogenesis. Towards the first goals, we will use transgenics to overexpress normal and mutated myosin light chains i the heart in a compartment specific manner such that athe protein complement of the heart is changed. Using cloned light chains and our cardiac specific promoters, a series of conditional transgenic animals will be made such that over expression and ectopic- isoform expression studies, as well as structure-activity studies can be done. Both the acute and chronic effects upon heart structure and function will be measured. These studies will use conditional expression transgenic models such that proteins encoded by the transgenes can be precisely modulated up/down during the animals' lifetime. The resultant mice will be analyzed at the molecular, biochemical, cellular and whole organ levels. In this manner, we will define whether or not a developing myopathy is due to a mutated protein and/or to stoichiometric perturbations in the levels of the contractile proteins that assemble to form the functional sarcomere. The second goal, to explore early cardiogenesis, involves the definition of the downstream targets of the morphogen, retinoic acid. We will use the a myosin heavy chain promoter to target a constitutively active retinoic acid receptor to the developing heart. The initial descriptive characterization will be followed by a concerted effort to identify the downstream genes that are activated, using a novel, dual screening approach. First, genomic fragments will be selected on the basis of t heir ability to bind the constitutively active retinoic acid receptor. These fragments will then be used to screen a normal genomic library. Clones isolated in this manner will then be screened with a probe population isolated via a differential PCR display obtained from developing hearts isolated from the mouse containing the constitutively active retinoic acid receptor and the nontransgenic littermates. In this manner, we hope to identify clones that are activated/deactivated by the morphogen's presence.
| Sadayappan, Sakthivel; Finley, Natosha; Howarth, Jack W et al. (2008) Role of the acidic N'region of cardiac troponin I in regulating myocardial function. FASEB J 22:1246-57 |
| Pattison, James Scott; Waggoner, Jason R; James, Jeanne et al. (2008) Phospholamban overexpression in transgenic rabbits. Transgenic Res 17:157-70 |
| Kalinichenko, Vladimir V; Gusarova, Galina A; Kim, Il-Man et al. (2004) Foxf1 haploinsufficiency reduces Notch-2 signaling during mouse lung development. Am J Physiol Lung Cell Mol Physiol 286:L521-30 |
| Small, Kersten M; McGraw, Dennis W; Liggett, Stephen B (2003) Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 43:381-411 |
| Sanbe, Atsushi; Gulick, James; Hanks, Mark C et al. (2003) Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. Circ Res 92:609-16 |
| Liggett, Stephen B (2003) Polymorphisms of adrenergic receptors: variations on a theme. Assay Drug Dev Technol 1:317-26 |
| Golovina, Vera A; Song, Hong; James, Paul F et al. (2003) Na+ pump alpha 2-subunit expression modulates Ca2+ signaling. Am J Physiol Cell Physiol 284:C475-86 |
| Lim, Lorena; Kalinichenko, Vladimir V; Whitsett, Jeffrey A et al. (2002) Fusion of lung lobes and vessels in mouse embryos heterozygous for the forkhead box f1 targeted allele. Am J Physiol Lung Cell Mol Physiol 282:L1012-22 |
| Pietri, Laurence; Bloch-Faure, May; Belair, Marie-France et al. (2002) Altered renin synthesis and secretion in the kidneys of heterozygous mice with a null mutation in the TGF-beta(2) gene. Exp Nephrol 10:374-82 |
| Schultz, Jo El J; Witt, Sandra A; Glascock, Betty J et al. (2002) TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 109:787-96 |
Showing the most recent 10 out of 257 publications
